Back to Search
Start Over
Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
- Source :
-
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2023 Jul; Vol. 22 (4), pp. 615-622. Date of Electronic Publication: 2023 Jan 10. - Publication Year :
- 2023
-
Abstract
- Background: With improvement in supportive therapies and the introduction of cystic fibrosis transmembrane conductance regulator (CFTR)-modulator treatment in patients with cystic fibrosis (CF), milder disease courses are expected. Therefore, sensitive parameters are needed to monitor disease course and effects of CFTR-modulators. Functional lung MRI using matrix-pencil decomposition (MP-MRI) is a promising tool for assessing ventilation and perfusion quantitatively. This study aimed to assess the treatment effect of elexacaftor/tezacaftor/ivacaftor combination regimen (ELX/TEZ/IVA) on measures of structural and functional lung abnormalities.<br />Methods: 24 children with CF underwent lung function tests (multiple breath washout, spirometry), functional and structural MRI twice (one year apart) before and once after at least two weeks (mean 4.7 ± 2.6 months) on ELX/TEZ/IVA. Main outcomes were changes (Δ) upon ELX/TEZ/IVA in lung function, defect percentage of ventilation (VDP) and perfusion (QDP), defect distribution index of ventilation and perfusion (DDI <subscript>V,</subscript> DDI <subscript>Q</subscript> ), and Eichinger score. Statistical analyses were performed using paired t-tests and multilevel regression models with bootstrapping.<br />Results: We observed a significant improvement in lung function, structural and functional MRI parameters upon ELX/TEZ/IVA treatment (mean; 95%-CI): ΔLCI <subscript>2.5</subscript> (TO) -0.84 (-1.62 to -0.06); ΔFEV <subscript>1</subscript> (z-score) 1.05 (0.56 to 1.55); ΔVDP (% of impairment) -6.00 (-8.44 to -3.55); ΔQDP (% of impairment) -3.90 (-5.90 to -1.90); ΔDDI <subscript>V</subscript> -1.38 (-2.22 to -0.53); ΔDDI <subscript>Q</subscript> -0.31 (-0.73 to 0.12); ΔEichinger score -3.89 (-5.05 to -2.72).<br />Conclusions: Besides lung function tests, functional and structural MRI is a suitable tool to monitor treatment response of ELX/TEZ/IVA therapy, and seems promising as outcome marker in the future.<br /> (Copyright © 2022. Published by Elsevier B.V.)
- Subjects :
- Humans
Child
Respiratory Function Tests
Spirometry
Magnetic Resonance Imaging
Lung diagnostic imaging
Aminophenols
Benzodioxoles
Mutation
Chloride Channel Agonists
Cystic Fibrosis Transmembrane Conductance Regulator genetics
Cystic Fibrosis diagnosis
Cystic Fibrosis drug therapy
Cystic Fibrosis genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5010
- Volume :
- 22
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
- Publication Type :
- Academic Journal
- Accession number :
- 36635199
- Full Text :
- https://doi.org/10.1016/j.jcf.2022.12.012